Back to mobile site

More on INAB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+72.6% Growth)
- Ratings (8.0 Score)

Upcoming Events

- Earnings (8/6/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

IN8bio, Inc (NQ:INAB)
Delayed: 1.43 -0.01 (0.69%)
Prev. Close $1.44  
Open$1.47 
52 Wk High$ 
52 Wk Low$ 
Day High$1.47 
Day Low$1.41 
P/E N/A  
EPS$ 
Volume14,085 


Jun 4, 2026 06:44 AM H.C. Wainwright Reiterates Buy Rating on IN8bio Inc. (INAB)
Jun 3, 2026 08:30 AM IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies
Jun 1, 2026 08:30 AM IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
Jun 1, 2026 06:56 AM Form 8-K IN8BIO, INC. For: May 29
Jun 1, 2026 06:18 AM Form 424B5 IN8BIO, INC.
May 29, 2026 05:41 PM Form SCHEDULE 13D/A IN8BIO, INC. Filed by: FAIRBAIRN EMILY
May 29, 2026 05:40 PM Form 4 IN8BIO, INC. For: May 27 Filed by: FAIRBAIRN EMILY
May 20, 2026 06:04 AM Form EFFECT IN8BIO, INC.
May 18, 2026 05:15 PM Form S-3/A IN8BIO, INC.
May 14, 2026 08:00 AM IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
View All Articles

Entities mentioned with INAB

View All Entities